RSRuchi Sankhwar

Ruchi Sankhwar

*This is an algorithmically generated author record based on publicly available information.

Ruchi Sankhwar has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lichenysin Produced by Bacillus licheniformis RG1002 Inhibit the Biofilm Formation of Pseudomonas aeruginosa on Various Surfaces

    by Abhishek Kumar, Ruchi Sankhwar, Shilpi Yadav, Ravi Kr. Gupta

    Pseudomonas aeruginosa is capable of producing biofilms on various surfaces, medical implants and burn wounds which inhibit the action of antimicrobial agents. This study was undertaken for the screening, identification and purification of a natural antimicrobial compound from the hospital waste sites against P. aeruginosa. The partial purification of the antimicrobial agent was performed with ethyl acetate from the culture supernatant of the isolate and further purified by HPLC. For the characterization of the active compound, we have used Fourier Transform Infrared Spectroscopy (FT-IR) and Electrospray Ionization mass spectrometry (ESI-MS) analysis. The purified compound was tested for anti-biofilm activity in vitro against P. aeruginosa and on various surfaces such as plastic, glass, and steel. The potent isolate was confirmed as Bacillus licheniformis strain RG1002. The HPLC purified compound was characterized as lichenysin using FTIR and ESI-MS analysis. This study identifies and characterize the potent antimicrobial agent against other important human pathogens such as Staphylococcus aureus, Salmonella typhi, Shigella flexneri and Escherichia coli. Purified lichenysin showed strong inhibitory effect against P. aeruginosa and other important pathogens and inhibits the biofilm formation of P. aeruginosa in vitro on various types of surfaces. The current study suggests the application of lichenysin as a protective coating on various indwelling medical devices and catheters to prevent the biofilm formation by P. aeruginosa.


  • Role and Application of CRISPR-Cas System in Genetic Disorders

    by Ravi Kr. Gupta, Shilpi Yadav, Ruchi Sankhwar, Abhishek Kumar

    CRISPR-Cas system has a potential role in diverse scientific fields such as agriculture, environment, and human health affected by familial or non-familial diseases. Interestingly, the absence of CRISP-Cas system in eukaryotes makes it a powerful tool for gene manipulation and editing in humans. Due to its low cost, easy manipulation, and straightforward mechanism, researchers find CRISPR-Cas systems the most advanced tool for gene therapeutics. Several clinical trials for the cure of human genetic disorders using CRISPR-Cas system are completed or underway. There are, however, some challenges with this technology, such as delivery of foreign DNA in the human body, host immune response, and risk of off-target mutations. However, we are very hopeful that in the near future scientists all over the world will find solutions for these hindrances and we can easily cure human genetic disorders. In this chapter we systematically explain the origin, mechanism of action, and application of CRISPR-Cas in human genetic disorders. The chapter will be very helpful for young researchers and students working in the field of gene therapeutics.